Dimensional Fund Advisors LP Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Dimensional Fund Advisors LP boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 14.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,429,615 shares of the biopharmaceutical company’s stock after buying an additional 433,318 shares during the period. Dimensional Fund Advisors LP’s holdings in Catalyst Pharmaceuticals were worth $84,908,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CPRX. WINTON GROUP Ltd grew its position in Catalyst Pharmaceuticals by 546.7% in the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock worth $8,251,000 after acquiring an additional 298,862 shares during the period. Merit Financial Group LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $654,000. Wakefield Asset Management LLLP purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $1,203,000. Universal Beteiligungs und Servicegesellschaft mbH raised its position in Catalyst Pharmaceuticals by 30.0% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 167,763 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 38,695 shares during the period. Finally, Stratos Wealth Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 21.2% in the 4th quarter. Stratos Wealth Advisors LLC now owns 117,721 shares of the biopharmaceutical company’s stock valued at $2,748,000 after purchasing an additional 20,628 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Get Catalyst Pharmaceuticals alerts:

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $31.49 on Friday. The business’s 50 day moving average is $31.41 and its two-hundred day moving average is $27.58. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The firm has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of research analyst reports. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Read Our Latest Report on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

Featured Stories

• Five stocks we like better than Catalyst Pharmaceuticals
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.